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Amyotrophic lateral sclerosis (ALS) is a devastating condition with an estimated mortality
of 30,000 patients a year worldwide. The median reported survival time since onset
ranges from 24 to 48 months. Riluzole is the only currently approved mildly efficacious
treatment. Riluzole received marketing authorization in 1995 in the USA and in 1996
in Europe. In the years that followed, over 60 molecules have been investigated as
a possible treatment for ALS. Despite significant research efforts, the overwhelming
majority of human clinical trials (CTs) have failed to demonstrate clinical efficacy. In the
past year, oral masitinib and intravenous edaravone have emerged as promising new
therapeutics with claimed efficacy in CTs in ALS patients. Given their advanced phase
of clinical development one may consider these drugs as the most likely near-term
additions to the therapeutic arsenal available for patients with ALS. In terms of patient
inclusion, CT with masitinib recruited a wider, more representative, less restrictive patient
population in comparison to the only successful edaravone CT (edaravone eligibility
criteria represents only 18% of masitinib study patients). The present manuscript reviews
>50 CTs conducted in the last 20 years since riluzole was first approved. A special
emphasis is put on the analysis of existing evidence in support of the clinical efficacy
of edaravone and masitinib and the possible implications of an eventual marketing
authorisation in the treatment of ALS.
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INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is the most common degenerative disease that affects the motor
neuron system. The disease was originally described by Charcot and Joffroy (1869). Despite the
nearly century and a half since the condition was first characterized, the extensive accumulated
scientific knowledge has not been sufficient to develop truly effective therapeutic strategies to
date. ALS primarily affects motor neurons in the brain, brainstem and the spinal cord, causing
progressive degeneration and atrophy of voluntary skeletal muscles ultimately resulting in paralysis
(Zufiría et al., 2016). The etiology of the disease has proven to be highly complex, undoubtedly
contributing to the lack of adequate treatment options. Only about 5–10% of ALS cases are familial
(fALS), with a Mendelian pattern of inheritance and at least 13 genes and loci of major effect known
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to contribute to familial pathology. Of these, toxic gain-of-
function mutations in the SOD1 (superoxide dismutase 1)
gene have been most extensively investigated. SOD1 mutations
account for approximately 20% of cases of fALS and around
5% of idiopathic/sporadic forms of the disease (sALS) (Kiernan
et al., 2011). The exact mechanisms whereby SOD1 contributes
to disease progression are currently unknown. Nevertheless, the
generation in 1993 of the first transgenic SOD1G93A mouse model
which closely mimics human fALS pathology was paradigmatic as
it has allowed the scientific community to investigate ALS disease
mechanisms in preclinical species for the first time (Gurney et al.,
1994). To this day, rodent SOD1 mutants remain as the most
widely employed ALS models to study both the cellular and
molecular disease mechanisms and to test the potential efficacy
of novel therapeutic compounds (Islam et al., 2014).
Riluzole is the only currently approved treatment option for
ALS patients in the US and in Europe, and is only mildly
efficacious. The drug received marketing authorisation in 1995 in
the USA and in 1996 in Europe. Even though the first large-scale
clinical trial (CT) demonstrating clinical efficacy of riluzole to
improve survival in ALS patients was conducted in 1990, 3 years
prior to the generation of the first SOD1 mouse model (Bensimon
et al., 1994), riluzole has subsequently been shown to have similar
efficacy in this transgenic model as seen in human ALS trials
(Gurney, 1997), thus validating the preclinical model. It is notable
that just like in human patients, riluzole failed to have beneficial
effect on disease onset and had only modestly improved survival
in these mice. The riluzole data were included in support of
the new drug application filed by Rhone-Poulenc-Rorer with the
United States Food and Drug Administration (Gurney, 1997). In
the years that followed, over 60 molecules have been investigated
as a possible treatment for ALS (Mitsumoto et al., 2014; DeLoach
et al., 2015). However, the vast majority of pharmaceuticals that
reached the CTs stage since riluzole’s approval have failed to
demonstrate clinical efficacy.
The aim of the present review is to catalog the results of
large-scale CTs that were conducted in the 20 years since riluzole
was first approved. An attempt is made to provide a methodical
overview of the chosen primary and secondary endpoints with
compounds grouped according to their principal mechanism
of action. An in-depth analysis is presented for edaravone and
masitinib – novel therapeutics that recently demonstrated clinical
efficacy in large-scale human CTs in ALS patients.
MATERIALS AND METHODS
In May–July 2016, a systematic search for randomized, placebo-
controlled clinical trials (RCTs) in ALS patients was performed
across the MEDLINE and Clinicaltrials.gov databases (published
in English language). In addition, ARISLA list of global ALS
trials (ARISLA (Fondazione Italiana de Ricerca Per La Sclerosi
Laterale), 2014) was used as a supportive information source.
Inclusion Criteria
Advanced phase (Phases II, II–III, and III) randomized controlled
trials (RCTs) that have recruited ≥100 ALS patients and with the
results published between 1995 and July 2016 were included. For
the compounds identified in this manner, the search was further
expanded to include all the early stage trials that served as a
justification for large-scale studies, regardless of the number of
patients recruited.
One compound, that did not meet pre-specified inclusion
criteria with 63 patients recruited in a Phases 2–3 RCT
(memantine; EudraCt # 2007-002117-39) was added to the
present analysis as this molecule’s mechanism of action (anti-
glutamatergic) is similar to the currently approved riluzole.
RESULTS
Clinical trials with 24 compounds, in addition to riluzole, are
presented in this analysis. Of the 23 molecules in advanced-stage
CTs, a total of 51 studies, with a cumulative recruitment of 13,427
ALS patients, are described (Table 1).
A wide range of compounds, representing at least 10 different
broadly defined mechanisms of action met the pre-specified
inclusion criteria. This both reflects on the disease complexity
and highlights the intensive research efforts put forth by the
academic scientists and the pharmaceutical industry.
Revised ALS Functional Rating Scale (ALSFRS-R) was chosen
as the primary endpoint in CTs with 11 (48%) of the 23 drugs
in advanced clinical development. 15 (65%) of compounds are
administered per os, 3 (13%) subcutaneously (s.c.), 3 (13%)
intravenously (i.v.), and a further 2 (9%) drugs via continuous
i.v. infusion.
Only two RCTs, which included pre-specified efficacy
measures as the primary endpoint and recruited ≥100 patients,
were successful on the primary endpoint. Based on the results
of pre-specified interim analysis, oral masitinib has shown
therapeutic benefit on the primary endpoint (ALSFRS-R), as well
as secondary endpoints of forced vital capacity (FVC), combined
assessment of function and survival (CAFS), and ALSAQ-40
(40-items ALS quality of life assessment questionnaire) (AB
Science, press-release www.ab-science.com/file_bdd/content/
1475163914_ABSCIENCESLAEMAFilingvEngVF.pdf) – in a
broad ALS patient population in advanced stage Phases 2–3
RCT. The study has recently completed recruitment (392
patients), with the results of the final analysis expected to be
available in 2017 (trial ID# NCT02588677). Edaravone is a
second drug that had shown clinical efficacy on the primary
endpoint (ALSFRS-R) and ALSAQ-40 secondary endpoint
in one of the three Phase 3 RCTs (trial ID# NCT01492686),
recruiting 137 patients (Tanaka et al., 2016a). The other two
RCTs with edaravone in ALS, which recruited patients with a
wider inclusion criteria (Abe et al., 2014), and patients with
more advanced disease (Tanaka et al., 2016b) have failed to
reach statistical significance on the primary endpoint. Edaravone
treatment regimen requires 2-weeks on, 2 weeks-off daily
continuous i.v. infusions (30 min) of the drug substance, a factor
which needs to be taken into consideration when assessing
quality of life. In terms of patient inclusion, CT with masitinib
recruited a wider, more representative, less restrictive patient
population in comparison to the only successful edaravone CT
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TABLE 1 | List of drugs and compounds tested in human ALS clinical trials.
Compound Route Primary endpoint/s Phase/s Outcome Fundingδ Reference
Anti-glutamatergic
Ceftriaxone i.v. ALSFRS-R; DTP 1–2; 3 Failure Academic Berry et al., 2013; Cudkowicz M. et al., 2013
Memantine Oral ALSFRS 2–3 Failure Academic de Carvalho et al., 2010
Riluzole Oral Survival 3 Mixed∗ Mixed Bensimon et al., 1994, 2002; Lacomblez et al., 1996
Talampanel Oral ALSFRS-R 2 Failure Industry Pascuzzi et al., 2010; Teva, 2010
Anti-inflammatory
Celecoxib Oral MVIC 2–3 Failure Industry Cudkowicz et al., 2006
Erythropoietin i.v. DTP 2; 3 Failure Academic Lauria et al., 2009, 2015
Glatiramer acetate s.c. ALSFRS-R 2; 2–3 Failure Industry Gordon et al., 2006; Meininger et al., 2009
Minocycline Oral ALSFRS-R 1–2; 3 Failure Academic Gordon et al., 2004, 2007; Pontieri et al., 2005
NP001 i.v. infusion ALSFRS-R 1; 2 Failure Industry Miller et al., 2014, 2015
Pioglitazone Oral Survival 2 Failure Industry Dupuis et al., 2012
Valproic acid Oral DTP 3 Failure Academic Piepers et al., 2009
Anti-oxidative
Coenzyme Q10 Oral ALSFRS-R 2 Failure Academic Ferrante et al., 2005; Kaufmann et al., 2009
Creatine Oral DTP; MVIC 2; 2–3; 3 Failure Academic Rosenfeld, 2001; Groeneveld et al., 2003; Shefner et al.,
2004; Rosenfeld et al., 2008; Pastula et al., 2012
Edaravone i.v. infusion ALSFRS-R 2; 3 Mixed∗∗ Industry Yoshino and Kimura, 2006; Abe et al., 2014; Palumbo
et al., 2016; Sakata et al., 2016; Tanaka et al., 2016a,b
Neuroprotective
Dexpramipexole Oral CAFS 2; 3 Failure Industry Cudkowicz et al., 2011; Cudkowicz M. E. et al., 2013;
Bozik et al., 2014
Olesoxime Oral Survival 2–3 Failure Mixed Lenglet et al., 2014
TCH346 Oral ALSFRS-R 2–3 Failure Industry Miller et al., 2007a
Xaliproden Oral MMT; DTP 2; 3 Failure Industry Lacomblez et al., 2004; Meininger et al., 2004
Neurotrophic factors
BDNF i.v. Survival; %FVC 1–2; 3 Failure Mixed Bradley, 1995; Kasarskis et al., 1999
CNTF s.c. MVIC 1; 1–2; 2–3; 3 Failure Mixed Miller et al., 1993, 1996; ALS CNTF Treatment Study
Group, 1995, 1996
IGF-1 s.c. AALS; MMT 3 Failure Mixed Lai et al., 1997; Borasio et al., 1998; Sorenson et al.,
2008
CSF1R inhibition
Masitinib Oral ALSFRS-R 2–3 Positive$ Industry
Other
Lithium Oral ALSFRS-R; Survival 2; 2–3; 3 Failure£ Mixed Fornai et al., 2008; Aggarwal et al., 2010; Verstraete
et al., 2012; Morrison et al., 2013
Tirasemtiv Oral ALSFRS-R 2 Failure Industry Shefner et al., 2012, 2013a,b, 2016
∗: Two out of three late-stage trials reported negative results; ∗∗: two out of three Phase 3 trials reported negative results; $: statistical significance reached on multiple
efficacy endpoints based on the results of interim analysis with 192 patients (50% of enrolled patients); £: only one pilot early phase trial reported statistical significance
on efficacy endpoints, all subsequent large-scale follow-up studies failed to reproduce these positive results.
δ: Reported funding source, as described by the authors of relevant publications.
AALS, Appel ALS Rating Scale; ALSFRS-(R), The ALS Functional Rating Scale (Revised); CAFS, combined assessment of function and survival; DTP, time to death,
tracheostomy or persistent assisted ventilation; %FVC, forced vital capacity; MMT, manual muscle test; MVIC, maximum voluntary isometric contraction; CSF1R, colony
stimulating factor 1 receptor; i.m., intramuscular i.v., intravenous; s.c., subcutaneous.
(edaravone eligibility criteria represents only 18% of masitinib
study patients).
Only one early stage trial (lithium), which included a
comparator arm and recruited <100 patients was successful on
the primary efficacy endpoint (Fornai et al., 2008). The limitation
of that study was that it recruited only 16 patients in the treatment
arm and 28 in the active control arm, randomization methods
were not clearly described, and the study utilized an open-label
design. All subsequent confirmatory RCTs with lithium have
failed to show evidence of clinical benefit (Aggarwal et al., 2010;
Verstraete et al., 2012; Morrison et al., 2013).
Of the 31 studies that included pre-specified efficacy measures
as the secondary endpoint(s) and recruited ≥100 patients, 26
studies did not reach statistical significance in any of the
secondary endpoints in the pre-defined analyses (including
studies that did not report P-values).
One study [Xaliproden (Lacomblez et al., 2004)] has reached
statistical significance in only one of the eight secondary
endpoints, and at only one of the two doses assessed. The
study failed on the primary endpoint. One study [Tirasemtiv
(Shefner et al., 2016)] has reached statistical significance in two
of the five secondary endpoints. The study failed on the primary
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endpoint. One study [IGF-1 (Lai et al., 1997)] has reached
statistical significance for the high-dose group in three out of
three secondary endpoints. The study failed on the primary
endpoint. Authors acknowledge that the treatment effect was very
modest and that the results of the study were inconclusive.
The other two compounds that reached statistical significance
on secondary endpoints are masitinib and edaravone. Both of
these drugs have also reported statistically significant treatment
effect on primary endpoints.
Detailed descriptions of the study designs and the treatment
outcomes for the CTs presented in Table 1 are available as
Supplemental Materials. As a significant number of original
publications do not provide comprehensive details on the way
the patient discontinuations are handled in study protocols, such
data is not presented as a part of the present Review.
DISCUSSION
The analysis of CTs presented in this systematic review is a
testament to the extraordinary complexity of the ALS disease
mechanisms. Even though academic science has made significant
progress in attempting to elucidate molecular, genetic, epigenetic
and environmental aspects of motor neuron degeneration, the
slow translational progress with only one approved drug on
the US and European markets suggests that existing preclinical
models are not fully representative of human disease process.
The absence of the fully characterized and validated rodent ALS
models is increasingly recognized as a major hurdle in clinical
development. In a recent study by ALS Therapy Development
Institute (ALS TDI), researchers performed rigorous animal
tests on multiple compounds which failed in CTs. Surprisingly,
the improvement in survival which was previously published
for all those drug candidates (including riluzole) could not
be replicated in an ALS TDI study (Perrin, 2014). Authors
emphasize the need for community effort in the area of preclinical
model development both by the public and private agencies. In
the meantime, currently available preclinical models should be
considered useful only to a certain extent, with the ultimate test
of the potential efficacy of any novel pharmaceutical having to
come from large-scale human CTs.
Up-to-date analysis of the state of the current understanding
of the molecular and other aspects of preclinical ALS research
had been presented in a number of recent review papers (Belzil
et al., 2016; Bozzoni, 2016; Clerc et al., 2016; Riva et al., 2016;
Therrien et al., 2016; Zufiría et al., 2016). While genetic mutations
in SOD1 gene undeniably contribute to the course of familial
ALS (fALS), it is only recently that we are beginning to uncover
additional factors that play a role in the etiology of sporadic ALS.
Taking into account that only about 10% of all patients present
with a fALS, with the remaining 90% of sufferers presenting with
sALS (Riva et al., 2016), it is of utmost importance that novel
therapeutics show clinical efficacy in sALS patient population.
Furthermore, recent epidemiological evidence suggests an
existing variation of ALS incidence between subcontinents that
might be related to population ancestries. While homogenous
incidence rates have been reported in populations from Europe,
North America and New Zealand, with pooled ALS standardized
incidence of 1.81 (1.66–1.97) per 100,000 person-years of
follow-up (PYFU), Asian populations appear to be distinct.
Differences were identified in ALS standardized incidence
between North Europe [1.89 (1.46–2.32)/100,000 PYFU] and
East Asia [0.83 (0.42–1.24)/100,000 PYFU, China and Japan,
P= 0.001] and South Asia [0.73 (0.58–0.89)/100,000 PYFU, Iran,
P = 0.02] (Marin et al., 2016). Such geographical variation
is an important factor that needs to be taken into account
when conducting global CTs and, for example, a hypothetical
compound showing clinical benefit in Asian population may
not necessarily be efficacious in European and North American
populations.
The following sections provide a brief overview of human
CTs with the molecules presented in Table 1 and Supplementary
Materials, grouped according to the putative mechanism of
action. A more in-depth discussion of the CT outcomes for
the two promising therapeutics, which claim potential clinical
efficacy in human CTs (edaravone and masitinib), is presented
in the latter part of this manuscript.
Anti-glutamatergic
It is thought that glutamate excitotoxicity plays a role in
the ALS pathogenesis (Rothstein, 1995). Glutamate is the
principal excitatory neurotransmitter in the central nervous
system. It is hypothesized that aberrant glutamatergic system
overactivation may lead to damage and an eventual death of
the motor neurons in ALS (Rothstein et al., 2005). Riluzole
is the only currently approved ALS treatment in the US and
in Europe, which moderately increases ALS patient survival
(by 2–3 months). The first-in-human CT with riluzole was
launched on the basis of the hypothesis that riluzole may
modulate glutamatergic transmission, which was supported by
pre-clinical data (Bensimon et al., 1994). Extensive research into
the mechanisms of action of riluzole have since then consistently
suggested that direct effects of riluzole on glutamate receptors
are limited, and usually require high concentrations, which are
not achieved in human patients. It is becoming increasingly
clear that the molecular effects of riluzole are manifold and
highly complex, including the modulation of persistent Na+
channel current, potentiation of calcium-dependent K+ current,
inhibition of neurotransmitter release, inhibition of fast Na+
current, inhibition of voltage-gated Ca2+ current and other
effects on neurotransmission (reviewed by Bellingham, 2011). It
is this complexity of neural effects of riluzole, which may explain
the failure in the CTs of other molecules which have targeted
glutamatergic transmission as their primary mechanism of action
(ceftriaxone, memantine, and talampanel). Despite the absence of
the clear consensus on the exact mechanism of action of riluzole
in ALS, the drug narrowly received marketing authorisation by
the FDA based on the results of three late-stage CTs, recruiting
over 1000 patients (Bensimon et al., 1994, 2002; Lacomblez et al.,
1996; Miller et al., 2007b).
Ceftriaxone is the only intravenous beta-lactam antibiotic
which was investigated in a large-scale non-stop Phases 1–3 RCT
recruiting 513 ALS patients (Berry et al., 2013; Cudkowicz M.
et al., 2013). The study was launched on the basis of existing
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evidence that beta-lactam antibiotics may have neuroprotective
(anti-excitotoxic) effects in a number of in vitro and in in vivo
preclinical models of ALS (Rothstein et al., 2005). Ceftriaxone
administration results in the upregulation of the glutamate
transporter GLT1, the primary molecule responsible for synaptic
glutamate inactivation. The drug delayed neuronal and muscle
strength loss, as well as increased survival in mouse ALS
models (Rothstein et al., 2005). The study failed to demonstrate
significant improvement in survival and functional outcomes in
ALS patients (Berry et al., 2013; Cudkowicz M. et al., 2013).
Similar rationale was used to launch a moderate-size CT with
memantine, a novel moderate-affinity voltage-dependent non-
competitive antagonist at glutamatergic NMDA receptors, which
preserves the physiological function of the receptor. Memantine
is currently approved for the treatment of Alzheimer disease. Just
like ceftriaxone, memantine prolonged survival in a SOD1G93A
mouse model of ALS (Wang and Zhang, 2005). A RCT with
63 patients failed to demonstrate any treatment effect in ALS
patients (de Carvalho et al., 2010). Talampanel is another
compound targeting glutamatergic transmission that failed in
advanced-stage CTs in ALS patients. Only the results of the failed
Phase 2 study with 58 patients were published in a peer-reviewed
journal (Pascuzzi et al., 2010). The data for the failed Phase 3
study, recruiting 559 patients (trial ID# NCT00696332) was not
publicly disclosed (Supplementary Materials).
Anti-inflammatory
Neuroinflammation is a prominent pathological finding in ALS
patients and is characterized by microglial activation, astrogliosis,
and infiltration of monocytes and T-cells. Neuroinflammatory
responses can be beneficial or harmful to motor neuron survival.
The release of signals from motor neurons represents the earliest
stages of ALS with microglia responding as an M2 phenotype,
releasing neuroprotective factors to repair motor neurons and
protect against further injury. As disease progresses, however,
the balance of neuroinflammatory mediators changes leading to
the exacerbation of the disease phenotype (Zhao et al., 2013).
Therapeutic regimens with an anti-inflammatory mechanism of
action may thus be of potential benefit to the ALS sufferers.
Seven compounds with primarily anti-inflammatory MoA are
presented in this manuscript. Unfortunately, all CTs with these
therapeutics have failed to show improvement on function in
ALS patients. All seven therapeutics, which include celexocib
(Cudkowicz et al., 2006), erythropoietin (Lauria et al., 2009,
2015), glatiramer acetate (Gordon et al., 2006; Meininger et al.,
2009), minocycline (Gordon et al., 2004, 2007; Pontieri et al.,
2005), NP001 (Miller et al., 2014, 2015), pioglitazone (Dupuis
et al., 2012), and valproic acid (Piepers et al., 2009) have
demonstrated preclinical efficacy in the SOD1 rodent models
of ALS. The failure of advanced-stage CTs has resulted in the
termination of the clinical development in ALS for all of the above
mentioned pharmaceuticals.
Anti-oxidative
The excessive production of reactive oxygen species and the
resultant oxidative stress and insufficient activity of antioxidant
defense mechanisms have been implicated in the pathogenesis
of many neurodegenerative diseases, including ALS (Li et al.,
2013). The involvement of the oxidative signaling pathways
in ALS pathology was considered as possible contributor to
disease course early on. As mentioned earlier, SOD1 transgenic
models are the most widely studied preclinical models of the
disease. Mutated SOD1 can form cytotoxic protein aggregates,
possibly leading to the loss of enzymatic function, or mutated
SOD1 may acquire cytotoxic properties (toxic gain-of-function)
(Saccon et al., 2013). As SOD1 plays a key role in reactive oxygen
clearance, defective enzymatic activity may potentially lead to
increased levels of oxidative stress (Niedzielska et al., 2015).
The presence of oxidative stress biomarkers was also previously
confirmed in the cerebrospinal fluid of living ALS patients (Tohgi
et al., 1999). Of the three compounds possessing anti-oxidative
properties described in this review, two compounds have failed
to demonstrate clinical efficacy in large CTs: creatine (Rosenfeld,
2001; Groeneveld et al., 2003; Shefner et al., 2004; Rosenfeld
et al., 2008; Pastula et al., 2012) and coenzyme Q10 (Ferrante
et al., 2005; Kaufmann et al., 2009). Edaravone is the only anti-
oxidative treatment which have demonstrated clinical efficacy on
the primary endpoint (ALSFRS-R) in one of the three Phase 3
CTs, which recruited 137 patients. The results of this trial were
presented as a conference abstract, and the complete data had not
been published as a full paper at the time of the submission of
this manuscript (Tanaka et al., 2016a). Nevertheless, edaravone
has received marketing authorisation exclusively in Japan in 2015.
A detailed overview of the clinical development of edaravone is
provided below in a separate section.
Creatine is a naturally occurring nitrogenous organic
acid found predominantly in the skeletal muscle where it
contributes to the production of adenosine triphosphate during
times of anaerobic metabolism (Bessman, 1987). It appears
to possess antioxidant and neuroprotective properties and
may improve mitochondrial function (Adhihetty and Beal,
2008). The publication of a report in 1999 that creatine
administration in SOD1G93A mutant mice produced a dose-
dependent improvement in motor performance and extended
survival (Klivenyi et al., 1999) has resulted in launch of a number
of large-scale human trials in ALS patients, both in the US
and in Europe (Groeneveld et al., 2003; Shefner et al., 2004;
Rosenfeld et al., 2008; Pastula et al., 2012). No clinical benefit
was demonstrated in any of human trials. Coenzyme Q10 is
an essential cofactor of the electron transport chain as well as
an important antioxidant, which is particularly effective within
mitochondria. Coenzyme Q10 administration also significantly
extended survival in an ALS mouse model (Beal, 2002), the results
which did not translate into success in human trials, which all
failed (Ferrante et al., 2005; Kaufmann et al., 2009).
Neuroprotective
Amyotrophic lateral sclerosis is a neurodegenerative disease
which results in the eventual destruction of the motor neuron.
Compounds which are potentially neuroprotective are thus
hypothesized to have an appreciable clinical benefit in ALS
patients. It is perhaps not surprising then, that therapeutics
that fall into this category have recruited very large patient
populations in their respective Phase 3 trials. CTs with olesoxime
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(Lenglet et al., 2014) and TCH346 (Miller et al., 2007a) have
recruited >500 patients each, with dexpramipexole (Cudkowicz
et al., 2011; Cudkowicz M. E. et al., 2013) and xaliproden
(Lacomblez et al., 2004; Meininger et al., 2004) recruiting >1000
and >2000 patients respectively (Supplementary Materials).
Dexpramipexole belongs to a class of compounds termed
benzothiazoles, structurally uncomplicated molecules with a
broad range of biological activity. In the central nervous system,
dexpramipexole has demonstrated mitochondrial function-
dependent neuroprotective activity in preclinical models,
including modest improvement in survival in the SOD1G93A
mouse model of ALS (Gribkoff and Bozik, 2008), which served
as a rationale for initiating clinical development. The compound
failed to demonstrate clinical benefit in ALS (Cudkowicz et al.,
2011; Cudkowicz M. E. et al., 2013).
Olesoxime is a cholesterol-like small molecule with the
neuroprotective mechanism thought to be dependent on
mitochondria. In line with the reoccurring pattern plaguing
ALS clinical development, the molecule improved motor
performance, delayed the onset of clinical disease, and extended
survival in SOD1G93A transgenic mice (Bordet et al., 2007), but
failed in the CT (Lenglet et al., 2014).
TCH346 is a small molecule which can be neuroprotective as
a result of the inhibition of both the apoptotic increases of the
glycolytic enzyme, glyceraldehyde 3-phosphate dehydrogenase
(GAPDH), and the nuclear accumulation of GAPDH (Carlile
et al., 2000). It is one the few compounds (together with
xaliproden), human clinical development of which was not
initiated based on positive data in SOD1 mutant models.
Rather, TCH346 treatment has demonstrated decreased loss
of motoneurons and motoneuron fibers in a mouse mutant
model of progressive motor neuronopathy (PMN), a hereditary
autosomal recessive wasting disease which shares some
symptoms of ALS (Sagot et al., 2000). Subsequent large-scale
CT in human ALS patients had failed to demonstrate clinical
efficacy on any of the functional endpoints (Miller et al., 2007a).
Xaliproden is a non-peptide compound of low molecular weight,
which was observed to promote the secretion or stimulate
receptors of several endogenous growth factors active on motor
neurons, thus conferring neuroprotection (Lacomblez et al.,
2004). Like TCH346, xaliproden delayed disease progression and
improved survival in a PMN mouse model (Duong et al., 1998).
The two Phase 3 CTs presented in current review are also the
largest, with the cumulative recruitment of >2000 patients. Both
studies featured identical design and were conducted in ALS
patients with (Study 2) or without (Study 1) background riluzole
therapy (Meininger et al., 2004). Both studies failed on primary
endpoints resulting in termination of clinical development
in ALS.
Neurotrophic Factors
Many neurotrophic factors are known to promote neuronal
survival and regeneration. As a result, a large number of these
factors have been investigated in preclinical models of ALS. These
include BDNF, CNTF, GDNF, IGF-1, VEGF, FGF; HGF, BMP-7,
and G-CSF (for an excellent review of neurotrophic factors both
in preclinical development and in CTs in ALS refer to Henriques
et al. (2010). Three factors were investigated in large-scale human
CTs. All failed to show improvement in human ALS patients. CTs
with brain-derived neurotrophic factor (BDNF) (Bradley, 1995;
Kasarskis et al., 1999), ciliary neurotrophic factor (CNTF) (Miller
et al., 1993, 1996; ALS CNTF Treatment Study Group, 1995,
1996) and insulin-like growth factor I (IGF-1) (Lai et al., 1997;
Borasio et al., 1998; Sorenson et al., 2008) are presented in Table 1
and Supplementary Materials.
Other
Lithium
Lithium is a special case in the history of the ALS CTs.
It is a compound used as a mood stabilizer and may have
potential neuroprotective properties. In an unusual report, which
published both the results of lithium treatment in SOD1G93A
mice and the results of a pilot human trial in the same publication,
authors found a remarkable improvement of survival in human
patients (Fornai et al., 2008). In a human trial which randomized
16 ALS patients into lithium + riluzole treatment arm versus
28 patients in the control arm (riluzole alone), no deaths were
reported in the treatment arm versus eight deaths (29%) in the
riluzole arm after a 15 months treatment period. Furthermore,
remarkable improvement was also reported for a number of
secondary functional endpoints. Understandably, the results of
this study generated considerable interest in the potential of
lithium as a treatment of ALS. No less than three CTs were quickly
launched by independent research groups in order to confirm the
results in double-blind randomized placebo-controlled studies
(the original study utilized an open-label design). Unfortunately,
all subsequent studies (Aggarwal et al., 2010; Verstraete et al.,
2012; Morrison et al., 2013) have failed to replicate the positive
results of the pilot trial. Lithium fiasco is a cautionary tale,
highlighting the importance of the use of appropriately chosen
patient populations, especially in a disease as difficult to treat
as ALS.
Tirasemtiv
Tirasemtiv is an orally bioavailable molecule that sensitizes
the troponin complex in fast-twitch skeletal muscle fibers to
calcium. A putative mechanism of action is an improvement
in the contraction of muscle in response to diminished neural
input thus potentially decreasing muscle fatigue (Shefner et al.,
2012). As muscle wasting is a symptom of ALS, a number of
human trials were launched in ALS patients (Shefner et al.,
2012, 2013a,b, 2016). The only large-scale Phase 2b study which
used a functional measure (ALSFRS-R) as the primary endpoint
and recruited 605 patients has failed on the primary endpoint
(Shefner et al., 2016). Because the study has shown statistical
significance on two out of five secondary endpoints (slow vital
capacity and muscle strength), the authors leave open the
possibility to potentially launch an additional Phase 3 study in
the future.
Edaravone
Edaravone is an intravenous free radical scavenger which
eliminates lipid peroxide and hydroxyl radicals and can thus
be classified as an anti-oxidative agent (Watanabe et al., 1994).
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As discussed earlier, oxidative stress is thought to contribute
to ALS pathology. Beneficial effects of edaravone have been
demonstrated in a preclinical model in wobbler mice with ALS-
like symptoms prior to the initiation of clinical development
(Yoshino and Kimura, 2006). First pilot CT of edaravone in
ALS employed an uncontrolled open-label design, did not use a
comparator arm and recruited a total of 19 patients randomized
into two dosage groups, with five patients receiving 30 mg daily
i.v. infusions, and the remaining 14 patients receiving 60 mg daily
i.v. infusions on a 2-weeks-on, 2-weeks-off schedule. Change
in ALSFRS-R was designated as the primary endpoint. Study
utilized an atypical design with the treatment effect calculated
on the basis of the functional decline on ALSFRS-R in the
same patients in the 6 months prior to treatment compared to
changes observed following 6 months of treatment. Nevertheless,
statistically significant treatment effect was observed on the
primary endpoint in the high-dose group.
The first confirmatory large-scale Phase 3 trial was launched
on the basis of the results of the pilot trial (Abe et al., 2014).
The study was an RCT which recruited a total of 206 patients
(placebo: 104; edaravone: 102). Patient inclusion criteria included
FVC of at least 70% and the time since disease onset of <3 years,
as well as allowed inclusion of patients with probable laboratory-
supported El Escorial criteria. ALSFRS-R was designated as
the primary endpoint. The study has failed to demonstrate
statistically significant treatment effect in any of the functional
endpoints. However, subgroup analysis revealed not-statistically
significant differences when patients were separated into three
subgroups according to the severity of the disease progression.
A trend was noted that edaravone appeared to show possible
treatment effect in patients with most severe and moderate
disease progression while no treatment effect was observed in
patients with least severe disease. Based on these results, two
additional confirmatory Phase 3 studies were launched. At the
time of the submission of this manuscript, the results of the
2nd and 3rd confirmatory studies were presented as conference
abstracts only and have not yet been published in peer-review
sources.
The second confirmatory Phase 3 study (trial ID#:
NCT00415519) recruited 25 patients with severe ALS, with
the inclusion criteria of FVC of at least 60% and the time since
disease onset of <3 years. The study failed to demonstrate any
treatment effect between placebo and edaravone arms (Tanaka
et al., 2016b).
The third confirmatory Phase 3 (Tanaka et al., 2016a) study
(trial ID#: NCT01492686) narrowed the inclusion criteria even
further (when compared to the first confirmatory study) and
excluded both the patients with more severe disease and the
patient population with the least severe disease (patients with
probable laboratory-supported ALS were no longer part of
inclusion criteria). Inclusion criteria included FVC of at least
80% and the time since disease onset of <2 years. This third
confirmatory Phase 3 trial recruiting 137 ALS patients was
successful on the primary endpoint of ALSFRS-R, as well
as on ALSAQ-40 quality-of-life questionnaire. Mean change
(±SE) in ALSFRS-R score was −7.50 ± 0.66 (placebo) and
−5.01 ± 0.64 (edaravone): a between group difference of
2.49 ± 0.76 (P = 0.001). Between group difference for ALSAQ40
was −8.79 ± 4.03 (P = 0.031). On the basis of the results of
the only successful confirmatory Phase 3 trial, edaravone received
marketing authorisation exclusively in Japan in 2015.
It is important to note that all CTs with edaravone
were conducted in Japanese population. As mentioned earlier,
epidemiological studies point to the existence of significant
difference in ALS incidence in populations of Asian versus
European/North American descents (Marin et al., 2016). If
edaravone is to become eventually available to the ALS sufferers
in Western countries, it will be beneficial to see a large-scale CT
with edaravone recruiting ALS patients of Western ancestry.
Patient burden can be considered as an additional factor
which should be taken into consideration. Edaravone treatment
requires continuous 30 min-long daily intravenous infusions on
a 2-weeks-on, 2-weeks-off schedule for an indefinite time period.
For a disease as severe as ALS this may be deemed acceptable,
however, in some markets such a route of administration may
require a hospital setting.
Masitinib
Masitinib is a highly selective tyrosine kinase inhibitor which
was previously shown to prevent CNS neuroinflammation in a
number of neurodegenerative disease models including in ALS
SOD1G93A rats (Piette et al., 2011; Vermersch et al., 2012; Kocic
et al., 2015; Trias et al., 2016). In a SOD1G93A rodent model,
masitinib significantly prolonged survival when delivered after
paralysis onset, an unprecedented effect in preclinical models
of ALS. Masitinib was also shown to be capable of controlling
microgliosis, neuroinflammation, and the emergence/expansion
of aberrant glial cells in preclinical ALS model. Masitinib’s
mechanism of action can thus be considered unique among the
compounds described in this review (Trias et al., 2016).
Masitinib is currently undergoing Phase 3 development
in ALS patients as an add-on to riluzole therapy (trial ID#
NCT02588677), recruiting 382 patients into three treatment arms
(placebo versus 3.0 and 4.5 mg/kg/day oral masitinib, with a 1:1:1
randomization). Patient recruitment has been completed at the
time this manuscript was submitted. A planned interim analysis
was carried out when 50% (191) patients had completed 48 weeks
of treatment, with ALSFRS-R as the primary endpoint. Results
demonstrated success on the primary ALSFRS-R endpoint (with
a significance level of P < 0.01) in the intent-to-treat population,
as well as significance in numerous sensitivity analyses of the
primary endpoint (AB Science, unpublished). Of note, the study
employed relatively broad patient inclusion criteria, including
patients with FVC of >60% and time since disease onset of less
<3 years. When these and other inclusion criteria are taken
into consideration, masitinib appears to have included a far
wider subgroup of ALS patients when compared with the only
successful edaravone confirmatory CT (the overall edaravone
subpopulation represents only 18% of patients that would have
been eligible for the masitinib trial).
The study will be completed when 100% of the enrolled
patients have completed the 48-week treatment protocol period.
Final data readout is expected before mid-2017. Considering
the near total failure of ALS CTs over the last 20 years,
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these results are encouraging and the prospects of an eventual
marketing authorization are currently being explored (AB
Science Press Release; www.ab-science.com/file_bdd/content/
1475163914_ABSCIENCESLAEMAFilingvEngVF.pdf).
It will be of interest to evaluate possible clinical potentials
of edaravone versus masitinib. Full publication of results from
clinical studies with both compounds in ALS will be of great
interest so that a more rigorous comparison of efficacy and safety
between these promising candidate treatments can be made.
However, given the information currently available and assuming
equivalence in all other aspects (e.g., efficacy, safety, and cost),
masitinib would appear to provide clinical advantages over
edaravone in terms of level of patient burden, which probably
translates to patient compliance. Furthermore, the only successful
edaravone CT have used strict inclusion criteria, with the clinical
benefit demonstrated in a population representative of only 18%
of ALS patients included in the masitinib trial. It will also be
of interest to see a clinical study of edaravone in ALS patients
of Western ancestries. Because this two drugs have different
mehanisms of action, it will be of interest to test whether or
not they may exhibit synergistic effects in animal models and
ultimately in CT in humans.
Non-pharmacologic and Symptomatic
Disease Management
In view of the current absence of adequate pharmacotherapy
for ALS patients and the fact that regulatory approval can
take years even for promising drug candidates, alternative
treatment options should not be overlooked. In recent years,
stem cell therapy has emerged as potential non-pharmacological
new treatment for patients with ALS. It is hypothesized that
stem cells may support dying motor neurons though reducing
inflammation, releasing growth factors, and other potential
mechanisms (Thomsen et al., 2014). Several pre-clinical and CTs
have used human bone marrow stromal-derived mesenchymal
stem cells (MSCs) that are differentiated into specialized neuron-
supporting cells to stably secrete neurotrophic factors. They
have been shown to exhibit MSC markers, display spindle-
like cell morphology, form single-cell-derived colonies, readily
differentiate into adipocytes and osteoblasts, and have the
capacity to express a number of neural genes (Blondheim et al.,
2006). To date, there are no peer-reviewed, proof-of-concept
studies using these cells in an ALS animal model and therefore
it is difficult to make assessments on the pre-clinical rationale for
their use in the treatment of ALS (Thomsen et al., 2014).
Multidisciplinary symptomatic care can lead to significant
improvement in the quality of life of individual patients.
However, supportive and symptomatic care does not usually fall
within the scope of primary endpoint analyses in well-controlled
RCTs, causing physicians to base their treatment opinions on
personal experience or literature reports which are frequently
based on anecdotal data (Jackson et al., 2015). Academic and
medical communities are increasingly recognizing the need
for evidence-based guidelines regarding the symptomatic care
in ALS patients including the management of such issues
as respiratory failure, nutrition, pain, fatigue, and cognitive
impairment. A number of palliative treatment options designed
to deal with the multiplicity of ALS symptoms have recently
been reviewed (Hobson and McDermott, 2016). Nevertheless,
additional well-controlled studies with the primary aim of
improving the quality-of-life of ALS patients will be welcome.
CONCLUSION
Nearly all of the CTs since riluzole was first approved have failed
to demonstrate clinical efficacy in the treatment of ALS. But now,
for the first time in the past 20 years, there is real encouragement
that we may soon have a new and more effective treatment
option available, pending approval from regulatory agencies. Two
potentially efficacious treatments are claiming to demonstrate
clinical benefit on functional endpoints in human CTs. Masitinib
and edaravone have passed the first significant milestones on
the road to potential approval in the US and European markets.
Even though edaravone already received marketing authorisation
in Japan based on mixed results from multiple CTs in Japanese
patients, the only successful CT with edaravone recruited a
restrictive ALS patient population. When compared to masitinib,
the edaravone trial targeted only around 18% of ALS patients
who would have been eligible to the masitinib trial. In case
of masitinib, the majority of recruited patients are of Western
ancestry, but claimed clinical efficacy is so far based on the results
of the successful unpublished interim analysis demonstrating
encouraging results on multiple study endpoints. However, the
study has already completed patient recruitment and full study
results are expected in 2017. Authors are cautiously optimistic
that one or more of the above mentioned treatments will become
available to ALS patients in the US and Europe in the near future.
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